Navigation Links
NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
Date:8/3/2009

Wu was vice president of business development at Genelabs Technologies Inc., where he was responsible for all business development and licensing activities, including search, evaluation, contract negotiations for all in- and out-license transactions as well as alliance management and assisting in corporate financing activities. At Genelabs, Wu completed numerous licensing agreements and research collaborations with companies including Novartis, Gilead and Affymetrix.

Prior to Genelabs, Wu participated in the 1997 establishment of Kissei Pharma, the U.S. subsidiary of Kissei Pharmaceuticals Co. of Japan. Wu also was director of business development for Quintiles-BRI, a clinical research organization, after working for 16 years at Syntex Corporation. At Syntex, he held numerous positions with increasing responsibility, beginning as a chemist at the Syntex Research Institute of Pharmaceutical Sciences and culminating as director of R&D Program Planning and Management for the company's Japanese subsidiary.

Wu received his MBA in International Finance from the University of San Francisco, School of Business. He has been a member of the American Association of Pharmaceutical Scientist Planning Committee for Harmonization of Pharmaceutical Science Requirements, the New York Pharma Forum, the Japan Society of Northern California, the Healthcare Study Group (JETRO New York), the Regulatory Affairs Professional Society, and the Licensing Executive Society and Drug Information Association. Wu has been a frequent speaker at conferences including the Bay Bio Panel, Hepatitis C in Search of a Cure, Conducting Clinical Trials in Japan, Pacific Rim Biotech Conference and BIO.

About NovaBay

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide(R) compounds, which are novel, synthetic anti-infective product candidates that are
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
2. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
3. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
6. Brookstone Pharmaceuticals Appoints New Corporate Position
7. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
8. Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
9. Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
10. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
11. BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 E-QURE Corp. (OTCQB: EQUR), ... Bio-electrical Signal Therapy device ("BST Device"), a new and ... heal chronic wounds, today announced that the Company has ... distributor specializing in medical devices, for the marketing and ... a 70 years old, sales, marketing and distribution company ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 ... "Global Market Study on 3D Cell Culture: ... published by Persistence Market Research, the global 3D cell culture ... is expected to expand at a CAGR of 29.1% ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:8/3/2015)... ... 2015 , ... Sterlitech Corporation introduces the compact, quiet, and ... laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free design, ... solution for a broad range of vacuum filtration applications. , Featuring a 1/7 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4Sterlitech Launches New Line of Vacuum Pumps 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4
... at 7:10 p.m. Eastern Time TodayBOTHELL, WA, and VANCOUVER, ... OGXI ) today announced the final results of ... presentation at the American Society of Clinical Oncology (ASCO) ... treated with OGX-011 in combination with docetaxel compared to ...
... and refractive eye surgery experts listed at Trusted LASIK ... recent American Society of Cataract and Refractive Surgery (ASCRS) ... Majmudar, Dr. Shachar Tauber, and Dr. William Trattler were ... Cup. The Challenge Cup is a competition between ...
... Brand collaborate with Seahorse Bioscience, Inc. to organize ... their years of experience studying promising disease pathways ... Seahorse Bioscience, Inc., the market leader in instruments ... their first Cellular Bioenergetics Workshop, " Understanding ...
Cached Biology Technology:OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 5OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 6OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 7OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer 8LASIK and Vision Correction Experts from Trusted LASIK Surgeons Directory Achieve Top Awards at ASCRS Meeting 2LASIK and Vision Correction Experts from Trusted LASIK Surgeons Directory Achieve Top Awards at ASCRS Meeting 3LASIK and Vision Correction Experts from Trusted LASIK Surgeons Directory Achieve Top Awards at ASCRS Meeting 4LASIK and Vision Correction Experts from Trusted LASIK Surgeons Directory Achieve Top Awards at ASCRS Meeting 5LASIK and Vision Correction Experts from Trusted LASIK Surgeons Directory Achieve Top Awards at ASCRS Meeting 6LASIK and Vision Correction Experts from Trusted LASIK Surgeons Directory Achieve Top Awards at ASCRS Meeting 7New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 2New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 3
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... the complex biological systems found at the sub-cellular ... the academic fields of biology and physics. However, ... of exciting advances in super-resolution imaging technologies. ... OShea, a biophysicist at the University of Nottingham, ...
... constantly exchanging materials through the movement of air ... rivers and the migration of animals across the ... another major driver of connectivity among ecosystems. In ... Ecology and the Environment, titled Continental-scale ecology in ...
... 30 Platinum Solutions, Inc. announced,it is part ... selected by the,Federal Bureau of Investigation to develop ... Division,s Next Generation,Identification (NGI) Program, an enhanced identification ... of the winning Lockheed Martin team, Platinum,Solutions will ...
Cached Biology News:Synergy between biology and physics drives cell-imaging technology 2Ecological globalization 2Platinum Solutions, Inc. Teams with Lockheed Martin on Federal Bureau of Investigation's Next Generation Identification Program 2
Sheep polyclonal to Trenbolone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: 17 alpha Trenbolone(3)-BTG....
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Biology Products: